Dimerix (ASX:DXB)
ASX announcement history & article coverage
Transparent by design.
Announcments by Dimerix (ASX:DXB) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Dimerix Secures A$34 Million Non-Dilutive Funding Facility
Trading Halt
Appendix 4G and Corporate Governance Statement
Appendix 4E and 2026 Annual Report
Dimerix reports $29.8 million loss, completes ACTION3 adult recruitment, expands global licensing with Everest Medicines
Dimerix Receives US$10M Upfront Payment from Everest
Dimerix receives US$10 million upfront from Everest Medicines for DMX-200 licensing in Asia
Dimerix Assumes Sponsorship of US IND for New Asset DMX-652
Dimerix Assumes U.S. IND Sponsorship for Phase 2 AKI Asset DMX-652
Dimerix Presents at Bioshares Summit 2026
Dimerix CEO Presents Diversification Strategy and Pipeline Progress at Bioshares Summit
Dimerix Quarterly Activities Report and Appendix 4C
Dimerix secures fifth licensing deal, expands pipeline with DMX-652 acquisition, and maintains strong funding through Phase 3 trial
Dimerix to Present at TechKnow Invest Conference 2026
US Patent Granted for Dimerix New Asset DMX-652
Dimerix secures US patent for DMX-652 with Phase 2 trial preparations underway for acute kidney injury
Dimerix Investor Webinar
Dimerix Expands Pipeline with Acquisition of Phase 2 Asset
Dimerix acquires Phase 2-ready AKI drug candidate DMX-652, expanding kidney disease pipeline
Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway
Trading Halt
DMX-200 Available To Patients Via Post-Trial Access Pathways
Dimerix to Provide Post-Trial Access to DMX-200 for FSGS Patients
Dimerix Investor Webinar
Dimerix Licenses DMX200 to Everest for China and Asia Region
Trading Halt